Safety of current antiviral drugs for chronic hepatitis B-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of current antiviral drugs for chronic hepatitis B

Published:2022-02-28 Issue:7 Volume:21 Page:939-945
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Masetti Chiara¹,Pugliese Nicola¹²^ORCID,Aghemo Alessio¹²,Viganò Mauro³

Affiliation:

1. Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy

2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy

3. Division of Hepatology, Ospedale San Giuseppe, Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2045271

Reference59 articles.

1. World Health Organization. 2021 [Available from https://www.who.int]. Accessed 2021 Oct 04.

2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

3. Chronic Hepatitis B Infection

4. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection

5. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B;Journal of Hepatology;2023-12

2. Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B;Medicine;2023-02-10

3. An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression;Science Advances;2022-12-23

4. Lactic Acidosis Adverse Drug Reaction Reporting Aspect Evaluation of Hepatitis B Treatment Using Korea Adverse Event Reporting System;Journal of Pharmacoepidemiology and Risk Management;2022-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3